Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-056293
Filing Date
2025-04-21
Accepted
2025-04-21 16:10:57
Documents
21
Period of Report
2025-06-03

Document Format Files

Seq Description Document Type Size
1 DEF 14A scph-20250421.htm   iXBRL DEF 14A 1172188
2 GRAPHIC img234107817_0.jpg GRAPHIC 21981
3 GRAPHIC img234107817_1.jpg GRAPHIC 33852
4 GRAPHIC img234107817_2.jpg GRAPHIC 21981
5 GRAPHIC img234107817_3.jpg GRAPHIC 21981
6 GRAPHIC img234107817_4.jpg GRAPHIC 240308
7 GRAPHIC img234107817_5.jpg GRAPHIC 242880
8 GRAPHIC img234107817_6.jpg GRAPHIC 457963
9 GRAPHIC img234107817_7.jpg GRAPHIC 178118
  Complete submission text file 0000950170-25-056293.txt   4716248

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT scph-20250421.xsd EX-101.SCH 12313
23 EXTRACTED XBRL INSTANCE DOCUMENT scph-20250421_htm.xml XML 275317
Mailing Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803
Business Address 25 BURLINGTON MALL ROAD, SUITE 203 BURLINGTON MA 01803 617-517-0730
scPharmaceuticals Inc. (Filer) CIK: 0001604950 (see all company filings)

EIN.: 465184075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38293 | Film No.: 25853244
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)